Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
WuSLiaoXZhuZHuangRChenMHuangAet al
McBean G
More exposure doesnt remove the need for discipline
At a glance Drug / evolocumab (Repatha), a PCSK9-inhibitor biologic antibody Supplement / glutathione (oral, liposomal, or IV forms) Known interaction / none documented in published literature or FDA label Interaction type / not applicable, no shared metabolic pathway identified Evolocumab clearance / proteolytic catabolism, not CYP450 or GSH-dependent Glutathione CYP effect / negligible at typical oral doses (250 to 1,000 mg/day) LDL-C reduction with evolocumab / up to 59% vs
Kannan R, Mittur A, Bao Y, Tsuruo T, Kaplowitz N
US$ 22.83
US$ 27.23
US$ 26.43
US$ 24.67
US$ 21.33
US$ 20.58
